Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Studies of Left Ventricular Dysfunction (SOLVD).

Dierdre Nauman1, Barry Greenberg

  • 1Division of Cardiology, Department of Medicine, Oregon Health Sciences University, Portland, OR.

The American Journal of Geriatric Cardiology
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predictors of Long-Term Outcomes in Hypertrophic Cardiomyopathy: The NHLBI HCM Registry.

JAMA·2026
Same author

Patient Perspectives on Cardiac Gene Therapy: A Survey of Knowledge, Attitudes, and Educational Needs.

Journal of cardiac failure·2026
Same author

Cardiology Provider Knowledge and Attitudes Toward Cardiac Gene Therapy: A Multi-Institutional National Survey.

JACC. Heart failure·2026
Same author

Angiotensin-Neprilysin Inhibition and Renal Outcome in Men and Women With Heart Failure.

Journal of the American Heart Association·2026
Same author

Finerenone and polypharmacy in heart failure with mildly reduced or preserved ejection fraction: a marker of risk, not a barrier to therapy.

European journal of heart failure·2026
Same author

Health status trajectories using Markov modeling in patients with heart failure with preserved ejection fraction.

Revista espanola de cardiologia (English ed.)·2026
Same journal

Systolic anterior motion of a retained anterior mitral valve leaflet following mitral valve replacement.

The American journal of geriatric cardiology·2008
Same journal

Biomarkers, age, and coronary artery remodeling in patients with acute coronary syndrome.

The American journal of geriatric cardiology·2008
Same journal

Electrocardiographic intervals in the healthy geriatric population--what are the "normals"?

The American journal of geriatric cardiology·2008
Same journal

Coronary events in persons aged 75 years or older in Finland from 1995 to 2002: the FINAMI study.

The American journal of geriatric cardiology·2008
Same journal

Sinus venosus atrial septal defect diagnosed at age 82.

The American journal of geriatric cardiology·2008
Same journal

Frailty, inflammation, and cardiovascular disease: evidence of a connection.

The American journal of geriatric cardiology·2008
See all related articles

Enalapril, an angiotensin-converting enzyme inhibitor, reduced all-cause mortality in patients with left ventricular dysfunction. This heart failure treatment also decreased cardiovascular mortality and progression to heart failure.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Congestive heart failure (CHF) has a high incidence and poor prognosis.
  • Effective treatments are crucial to reduce CHF morbidity and mortality.

Purpose of the Study:

  • To evaluate the effect of enalapril, an angiotensin-converting enzyme inhibitor, on all-cause mortality in patients with left ventricular dysfunction.
  • To assess secondary outcomes including cause-specific mortality, heart failure development, and hospitalization.

Main Methods:

  • The Studies of Left Ventricular Dysfunction (SOLVD) trial randomized patients with ejection fraction ≤35% into treatment and prevention arms.
  • The trial was double-blind and placebo-controlled with a mean follow-up of 39.2 months.

Main Results:

Related Experiment Videos

  • The treatment arm showed a 16% risk reduction in all-cause mortality (P=0.008).
  • The prevention arm demonstrated a 37% risk reduction in progression to heart failure (P<0.001) and a 12% reduction in cardiovascular mortality (P=0.12).

    • Conclusions:

    • Enalapril therapy provides significant benefits for morbidity and mortality in a wide range of patients with left ventricular dysfunction.
    • Angiotensin-converting enzyme inhibitors are effective in managing heart failure and improving patient outcomes.